EXITINE 0.5MG/5ML SOLUTION FOR IV INJECTION

Indications

• Reversal of sedative effects of benzodiazepines
• Management of benzodiazepine overdose

Dosage

Children: In neonates and children, 10 micrograms/kg may be administered every 1 minute as needed, up to a maximum of 200 micrograms per dose.

Adults: 300 micrograms administered by intravenous injection over 15 seconds, may be repeated if necessary.

Mechanism of action

Flumazenil competitively inhibits the benzodiazepine binding site on the GABA/benzodiazepine receptor complex. While it is a weak partial agonist in certain animal models, it shows little to no agonist activity in humans. This action effectively reverses the central nervous system depressant effects produced by benzodiazepines without affecting the actions of other sedative drugs.

Pharmacodynamics

Flumazenil effectively antagonizes the central nervous system effects caused by benzodiazepines. However, it does not reverse effects caused by other agents that interact with GABA-ergic neurons through different mechanisms, such as ethanol, barbiturates, or general anesthetics. It also does not antagonize the effects of opioids, highlighting its specific action on benzodiazepine receptors.

Pharmacokinetics

Flumazenil is administered intravenously, and its pharmacokinetics include rapid distribution and elimination, contributing to its effectiveness in acute settings. The drug has a relatively short half-life, which necessitates careful monitoring of patients after administration, as the effects of benzodiazepines may recur once Flumazenil is metabolized.

Contra-indications

• Hypersensitivity to flumazenil or any of its components
• Patients who have been administered benzodiazepines for life-threatening conditions
• Co-administration with benzodiazepines

Adverse effects

• Nausea
• Vomiting
• Dizziness
• Headache
• Seizures
• Arrhythmias

Interactions

• May precipitate withdrawal seizures in patients dependent on benzodiazepines
• Does not reverse the effects of opioids or drugs affecting GABA-ergic neurons through pathways other than the benzodiazepine receptor

Precautions

• Use with caution in patients with seizure disorders
• Consider potential for withdrawal symptoms in long-term benzodiazepine users
• Monitor respiratory and cardiovascular status during administration
• Not recommended for routine use in reversing conscious sedation

Pregnancy

Flumazenil should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus. Safety in pregnancy has not been established.

Breast-feeding

Caution is advised as it is not known whether flumazenil is excreted in human milk.

Storage

Store at room temperature, protect from light. Keep out of reach of children.

Formulations

• Solution for injection (50 mg/mL)

Mechanism of action

Flumazenil, an imidazobenzodiazepine derivative, is a benzodiazepine antagonist. It competitively inhibits the benzodiazepine binding site on the GABA/benzodiazepine receptor complex. Flumazenil is a weak partial agonist in some animal models of activity, but has little or no agonist activity in man.

Pharmacodynamics

Flumazenil antagonizes the CNS effects produced by benzodiazepines, but does not antagonize the central nervous system effects of drugs affecting GABA-ergic neurons by means other than the benzodiazepine receptor (including ethanol, barbiturates, or general anesthetics) and does not reverse the effects of opioids.